{"id":"W4414377875","doi":"10.1016/j.jtcvs.2025.09.017","title":"TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic and Cardiovascular Surgery","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute; AstraZeneca","keywords":"Clinical endpoint; Stage (stratigraphy); Adenocarcinoma; Adjuvant; Lung cancer; Randomized controlled trial; Phases of clinical research; Adjuvant therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00205989,0.001987448,0.002745599,0.0007032737,0.0005396858,0.001603022,0.001266769,0.001751278,0.004882615],"category_scores_gemma":[0.0008324589,0.0008797881,0.002432115,0.0006972586,0.001367942,0.0009388484,0.0005601491,0.004586138,0.001314015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001371241,"about_ca_system_score_gemma":0.002099524,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003741997,"about_ca_topic_score_gemma":0.01049725,"domain_scores_codex":[0.9993281,0.0003039629,0.0000262761,0.00009863562,0.00006005407,0.0001829017],"domain_scores_gemma":[0.9994227,0.00007097213,0.00008830838,0.00005748518,0.00003710641,0.000323553],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.756741,0.07162713,0.008135324,0.001304276,0.002794482,0.0002075455,0.0004554003,0.003416382,0.0389899,0.000375359,0.0056107,0.1103425],"study_design_scores_gemma":[0.6190552,0.3622682,0.009677755,0.00006260644,0.0009695353,0.0002511073,0.0001128513,0.0006926185,0.002965494,0.0001539455,0.00374486,0.00004578075],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877831,0.004035725,0.0004994542,0.0006495512,0.0001968235,0.002726299,0.001993664,0.0001808473,0.001934595],"genre_scores_gemma":[0.9744133,0.005017724,0.002496898,0.001702381,0.0002076994,0.004239095,0.006379425,0.0001071262,0.00543637],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004882615,"threshold_uncertainty_score":0.01633394,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01563828591311364,"score_gpt":0.3483685570031425,"score_spread":0.3327302710900288,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}